Home » Regions » Global News » Neuropore, UCB enter world-wide collaboration and agreement

Neuropore, UCB enter world-wide collaboration and agreement

Monday, January 19, 2015

Neuropore Therapies, a wholly owned U.S. subsidiary of Austria-based Ever Neuro Pharma, and UCB, a Brussels, Belgium-based global biopharmaceutical company, have entered into a worldwide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein, which currently is in preclinical development and is expected to enter clinical phase I in 2015.

“Parkinson’s disease is a debilitating neurodegenerative disorder that results in disruption of normal movement and motor function, as well as cognitive and other life-altering symptoms,” said Ismail Kola, president UCB New Medicines. “People living with Parkinson’s disease need better treatment options, especially as there currently is no approved treatment that addresses a fundamental pathological mechanism in Parkinson’s disease. With Neuropore’s NPT200-11, we have the opportunity to develop a disease modifying treatment option for patients with Parkinson’s disease and other synucleinopathies.”

UCB will receive the worldwide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first phase I study to be initiated in 2015. UCB will lead all further clinical development, regulatory activities and commercialization. Neuropore will receive an initial upfront payment of $20 million and is entitled to potential development, regulatory and sales-based milestones payments of up to $460 million, in addition to royalties on net sales.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!